Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Toward a rational selection of treatment for addiction.

× No keyword cloud information.

14 in total

1. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors: Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal: J Biol Chem Date: 2005-07-26 Impact factor: 5.157

2. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade.

Authors: Gary S Wand; Mary McCaul; Xioaju Yang; Joanna Reynolds; Deidre Gotjen; Shing Lee; Ahmed Ali
Journal: Neuropsychopharmacology Date: 2002-01 Impact factor: 7.853

3. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.

Authors: Joel Gelernter; Ralitza Gueorguieva; Henry R Kranzler; Huiping Zhang; Joyce Cramer; Robert Rosenheck; John H Krystal
Journal: Alcohol Clin Exp Res Date: 2007-04 Impact factor: 3.455

4. Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: potential in studies of addiction.

Authors: K S LaForge; V Shick; R Spangler; D Proudnikov; V Yuferov; Y Lysov; A Mirzabekov; M J Kreek
Journal: Am J Med Genet Date: 2000-10-09

5. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden.

Authors: Gavin Bart; Mary Jeanne Kreek; Jurg Ott; K Steven LaForge; Dmitri Proudnikov; Lotta Pollak; Markus Heilig
Journal: Neuropsychopharmacology Date: 2005-02 Impact factor: 7.853

6. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.

Authors: Jörn Lötsch; Carsten Skarke; Sabine Grösch; Jutta Darimont; Helmut Schmidt; Gerd Geisslinger
Journal: Pharmacogenetics Date: 2002-01

7. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.

Authors: Lara A Ray; Kent E Hutchison
Journal: Arch Gen Psychiatry Date: 2007-09

8. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors: C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal: Proc Natl Acad Sci U S A Date: 1998-08-04 Impact factor: 11.205

9. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens.

Authors: R A Gonzales; F Weiss
Journal: J Neurosci Date: 1998-12-15 Impact factor: 6.167

10. Naltrexone in the treatment of alcohol dependence.

Authors: J R Volpicelli; A I Alterman; M Hayashida; C P O'Brien
Journal: Arch Gen Psychiatry Date: 1992-11